Guokui Qin
About
Guokui Qin is from Greater Boston. Guokui is currently Director, Global Research at CANbridge Pharmaceuticals Inc. , located in Greater Boston. In Guokui's previous role as a Principal Scientist/Head of Biologics Discovery and Characterization at Simcere Innovation, Guokui worked in Cambridge, Massachusetts, United States until Jan 2021. Prior to joining Simcere Innovation, Guokui was a Principal Scientist at Quad Technologies/Bio-Techne Corporation and held the position of Principal Scientist at Woburn, MA. Prior to that, Guokui was a Research Director at Quad Technologies, based in Woburn, MA from Jul 2015 to Jul 2018. Guokui started working as Research Scientist at Massachusetts Institute of Technology (MIT) in Department of Chemical Engineering, Massachusetts Institute of Technology in May 2013. From Jan 2011 to May 2013, Guokui was Research Associate at Tufts University, based in Department of Biomedical Engineering, Tufts University. Prior to that, Guokui was a Postdoctoral Associate at Tufts University, based in Department of Biomedical Engineering, Tufts University from Jul 2007 to Dec 2010.
Guokui Qin's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Guokui Qin's current jobs
Direct exploratory antibody-based drug discovery studies with the goal of discovering transformative first-in-class medicines for autoimmune disorders and rare disease treatment, using protein/antibody engineering beyond traditional mAbs including alternative non-Ig scaffolds, bispecific antibodies and fusion proteins.
Guokui Qin's past jobs
Experienced scientific research leader for antibody-related drug discovery within innovative biopharma company, and initiated and managed several research projects, including antibody discovery/screening, antibody engineering and production, and functional validation of antibody therapeutics for cancer/tumor immunotherapies. • Directed Antibody Discovery and Protein Characterization team to establish robust mammalian cell transfection, purification and functional validation platforms for antibody/protein therapeutic products • Worked closely with executive leadership to formulate proof-of-concept strategies and led the pre-clinical research programs for the treatment of blood cancer and solid tumors • Provided scientific support and quality assessment of antibody therapeutics to meet project requirements • Support internal CAR-T and CAR-NK cell therapy research projects to further evaluate pharmacological therapeutic strategies for the treatment of blood cancer and solid tumors
• As a Principal Investigator, received NSF SBIR Phase II award (awarded amount: $750,000.00) (withdrawn because of acquisition with Bio-Techne Corporation) • Process development for target cell separation, cell activation and expansion with specific antibody selection • Functional/biochemical assay optimization for target antibody affinity/binding, titration and stability
The leading inventor of novel mammalian cell separation and activation technology. Brought technologies from initial concepts to successful goal achievement through in house exploratory studies under NSF governmental Small Business Innovation Research grants and contracts in areas of cell therapies. • As a Principal Investigator, received NSF SBIR/STTR Phase I award (awarded amount: $225,000.00) • As a leading inventor, filed 3 patent applications covering the core intellectual property on cell therapy workflows, including cell separation, cell activation and expansion with specific antibody selection • Generated initial data sets to enable purification of highly specific mammalian cell populations with improved target cell purity to streamline CAR-T cell therapy biomanufacturing workflows • Developed efficient conjugation technologies for highly efficient cell purification
• Led several research projects and built a highly efficient molecular biology and protein biochemistry platform for plasmid construction, protein expression, purification and biophysical characterization • Designed purification strategies for recombinant proteins from a variety of host cells (eukaryotic and prokaryotic), and executed routine protein purification chromatography technologies • Expressed and purified recombinant protein examples: elastin, mCherry, lipase, human myoglobin, cytochrome P450, EGFP, bacterial S-layer proteins, etc.
• Created a new biomedical system using recombinant proteins/peptides for drug/gene delivery • Cloned, purified and characterized for the first time camouflage peptides featured in MaterialsViews • Engineered a ‘gene circuit’ system for signal rapid detection using genetic engineering technique • Innovated and pioneered the studies of a super elastic protein: plasmid cloning, protein expression and purification, quantitative and kinetic assessment and functional characterization with biophysical methods
• A super elastic natural protein biopolymer: gene cloning, expression and elasticity characterization of natural elastic biomolecules • Investigation of molecular mechanism of elasticity for protein-based materials • Bioengineered molecules with new functional binding domains related to a range of new biomolecular properties for drug and gene delivery